Susceptibility to invasive bacterial infections in children with sickle cell disease

Pediatric Blood and Cancer

Volumn 55, Issue 3, 2010, Pages 401-406

  Battersby, Anna J ^a   Knox Macaulay, Huxley H M ^b   Carrol, Enitan D ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

Bacteremia; Bacterial; Immune; Infection; Sickle cell

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; LYMPHOTOXIN; PNEUMOCOCCUS VACCINE; THROMBOCYTE ACTIVATING FACTOR;

AFRICA; ANTIBIOTIC PROPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BACTERIAL INFECTION; CAUSE OF DEATH; COMPLEMENT SYSTEM; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; INFECTION SENSITIVITY; MORTALITY; NONHUMAN; OPSONIZATION; PATIENT COMPLIANCE; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; SALMONELLA; SICKLE CELL ANEMIA; SPLEEN; STREPTOCOCCUS PNEUMONIAE; DISEASE PREDISPOSITION; GENETICS; HAEMOPHILUS INFECTION; IMMUNOLOGY; MICROBIOLOGY; PRESCHOOL CHILD; SALMONELLOSIS;

ANEMIA, SICKLE CELL; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; CHILD, PRESCHOOL; DISEASE SUSCEPTIBILITY; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SALMONELLA INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 77955494173     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22461     Document Type: Review

References (63)

1. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480-487.
2. World Health Organisation Sickle cell anaemia: Report by the secretariat. 2006.
3. NCEPOD. A sickle crisis? A report of the national confidential enquiry into patient outcome and death. London: NCEPOD; 2008.
4. Dick MC. Standards for the management of sickle cell disease in children. Arch Dis Child Educ Pract Ed 2008;93:169-176.
5. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
6. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative study of sickle cell disease. Blood 1995;86:776-783.
7. Thomas AN, Pattison C, Serjeant GR. Causes of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed) 1982;285:633-635.
8. Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: A clinic-based population study. Lancet 2001;357:680-683.
9. Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Rev 1989;3:18-28.
10. Athale UH, Chintu C. Clinical analysis of mortality in hospitalized Zambian children with sickle cell anaemia. East Afr Med J 1994; 71:388-391.
11. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004;103:4023-4027.
12. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr 2003; 143:438-444.
13. Powars D, Overturf G, Turner E. Is there an increased risk of haemophilus influenzae septicemia in children with sickle cell anemia? Pediatrics 1983;71:927-931.
14. Raghupathy R, Haider MZ, Azizieh F, et al. Th1 and Th2 cytokine profiles in sickle cell disease. Acta Haematol 2000;103:197-202.
15. Miller ML, Gao G, Pestina T, et al. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. J Infect Dis 2007; 195:581-584.
16. Davies EG, Riddington C, Lottenberg R, et al. Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev 2004; CD003885.
17. Kizito ME, Mworozi E, Ndugwa C, et al. Bacteraemia in homozygous sickle cell disease in Africa: Is pneumococcal prophylaxis justified? Arch Dis Child 2007;92:21-23.
18. Akuse RM.Variation in the pattern of bacterial infection in patients with sickle cell disease requiring admission. J Trop Pediatr 1996; 42:318-323.
19. Akinyanju O, Johnson AO. Acute illness in Nigerian children with sickle cell anaemia. Ann Trop Paediatr 1987;7:181-186.
20. Aken'ova YA, Bakare RA, Okunade MA. Septicaemia in sickle cell anaemia patients: The Ibadan experience. Cent Afr J Med 1998; 44:102-104.
21. Williams TN, Uyoga S, Macharia A, et al. Bacteraemia in Kenyan children with sickle-cell anaemia: A retrospective cohort and case-control study. Lancet 2009;374:1364-1370.
22. Workman MR, Philpott-Howard JN, Casewell MW, et al. Salmonella bacteraemia in sickle cell disease at king's college hospital: 1976-1991. J Hosp Infect 1994;27:195-199.
23. MacLennan CA, Gondwe EN, Msefula CL, et al. The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of salmonella in African children. J Clin Invest 2008;118:1553-1562.
24. Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985; 76:392-397.
25. William BM, Corazza GR. Hyposplenism: A comprehensive review. Part i: Basic concepts and causes. Hematology 2007; 12:1-13.
26. Obaro S. Pneumococcal infections and sickle cell disease in Africa: Does absence of evidence imply evidence of absence? Arch Dis Child 2009;94:713-716.
27. Adekile AD, McKie KM, Adeodu OO, et al. Spleen in sickle cell anemia: Comparative studies of Nigerian and U.S. patients. Am J Hematol 1993;42:316-321.
28. Williams LW, Burks AW, Steele RW. Complement: Function and clinical relevance. Ann Allergy 1988;60:293-300.
29. Janoff EN, Rubins JB. Invasive pneumococcal disease in the immunocompromised host. In: Tomasz A, editor. Streptococcus pneumoniae. New York: Mary Ann Liebert; 2000.
30. Rautonen N, Martin NL, Rautonen J, et al. Lownumber of antibody producing cells in patients with sickle cell anemia. Immunol Lett 1992;34:207-211.
31. DeCeulaer K, Wilson WA, Morgan AG, et al. Plasma haemoglobin and complement activation in sickle cell disease. J Clin Lab Immunol 1981;6:57-60.
32. Wilson WA, Thomas EJ, Sissons JG. Complement activation in asymptomatic patients with sickle cell anaemia. Clin Exp Immunol 1979;36:130-139.
33. Taylor SC, Shacks SJ, Villicana SM, et al. Interferon production in sickle cell disease. Lymphokine Res 1990;9:415-423.
34. Kaul DK, Tsai HM, Liu XD, et al. Monoclonal antibodies to alphavbeta3 (7e3 and lm609) inhibit sickle red blood cell - endothelium interactions induced by platelet-activating factor. Blood 2000;95:368-374.
35. Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for plateletactivating factor. Nature 1995;377:435-438.
36. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS) allele and sickle cell disease: A HuGe review. Am J Epidemiol 2000;151:839-845.
37. Knox-Macaulay HH, Ahmed MM, Gravell D, et al. Sickle cellhaemoglobin E (HbSE) compound heterozygosity: A clinical and haematological study. Int J Lab Hematol 2007;29:292-301.
38. Magnus SA, Hambleton IR, Moosdeen F, et al. Recurrent infections in homozygous sickle cell disease. Arch Dis Child 1999;80:537-541.
39. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005;129:465-481.
40. Adekile AD, Tuli M, Haider MZ, et al. Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Am J Hematol 1996;53:1-5.
41. Wali YA, Al-Lamki Z, Hussein SS, et al. Splenic function in Omani children with sickle cell disease: Correlation with severity index, hemoglobin phenotype, iron status, and alpha-thalassemia trait. Pediatr Hematol Oncol 2002;19:491-500.
42. Tamouza R, Neonato MG, Busson M, et al. Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum Immunol 2002;63:194-199.
43. Tamouza R, Busson M, Fortier C, et al. HLA-E*0101 allele in homozygous state favors severe bacterial infections in sickle cell anemia. Hum Immunol 2007;68:849-853.
44. Norris CF, Surrey S, Bunin GR, et al. Relationship between Fc receptor IIa polymorphism and infection in children with sickle cell disease. J Pediatr 1996;128:813-819.
45. Neonato MG, Lu CY, Guilloud-Bataille M, et al. Genetic polymorphism of the mannose-binding protein gene in children with sickle cell disease: Identification of three new variant alleles and relationship to infections. Eur J Hum Genet 1999;7:679-686.
46. Adewoye AH, Nolan VG, Ma Q, et al. Association of polymorphisms of IGFR1 and genes in the transforming growth factor-beta/bone morphogenetic protein pathway with bacteremia in sickle cell anemia. Clin Infect Dis 2006;43:593-598.
47. Koskela M, Leinonen M, Haiva VM, et al. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986;5:45-50.
48. Wright PF, Sell SH, Vaughn WK, et al. Clinical studies of pneumococcal vaccines in infants. II. Efficacy and effect on nasopharyngeal carriage. Rev Infect Dis 1981;3:S97-S107.
49. Dagan R, Melamed R, Muallem M, et al. Nasopharyngeal colonization in southern Israel with antibiotic-resistant pneumococci during the first 2 years of life: Relation to serotypes likely to be included in pneumococcal conjugate vaccines. J Infect Dis 1996; 174:1352-1355.
50. Overturf GD, Selzer JW, Chan L, et al. Pneumococcal polysaccharide immunization of children with sickle cell disease. II. Serologic response and pneumococcal disease following immunization. Am J Pediatr Hematol Oncol 1982;4:25-35.
51. Hardie R, King L, Fraser R, et al. Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening. Ann Trop Paediatr 2009;29:197-202.
52. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente vaccine study center group. Pediatr Infect Dis J 2000;19:187-195.
53. Halasa NB, Shankar SM, Talbot TR, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007;44:1428-1433.
54. Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7- valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008;121:562-569.
55. Howard-Jones M, Randall L, Bailey-Squire B, et al. An audit of immunisation status of sickle cell patients in Coventry, UK. J Clin Pathol 2009;62:42-45.
56. Overturf GD, Field R, Lam C, et al. Nasopharyngeal carriage of pneumococci in children with sickle cell disease. Infect Immun 1980;28:1048-1050.
57. Riddington C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 2002; CD003427.
58. John AB, Ramlal A, Jackson H, et al. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed) 1984;288:1567-1570.
59. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia.Arandomized trial.N Engl J Med 1986;314:1593-1599.
60. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II. J Pediatr 1995;127:685-690.
61. Daw NC,Wilimas JA,Wang WC, et al. Nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae in children with sickle cell disease. Pediatrics 1997;99:E7.
62. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines 2009;8:977-986.
63. CDC. Recommended immunization schedules for persons aged 0-18 years - United States. MMWR 2008;57:Q1-Q4.